Citius Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Citius Pharmaceuticals CEO Leonard L. Mazur extended the expiration dates of two tranches of warrants and updated his beneficial ownership of common stock and stock options.
NASDAQ
Citius Pharmaceuticals' Vice Chairman Myron Z. Holubiak reported warrant term extensions and detailed various stock option holdings in a recent SEC filing.
NASDAQ
Director Carol Webb of Citius Pharmaceuticals acquired 125,000 shares through stock options, as detailed in a recent SEC Form 4 filing.
NASDAQ
A Citius Pharmaceuticals director, Robert Joseph Smith, has acquired stock options for 125,000 shares at an exercise price of $0.38 and 75,000 shares at an exercise price of $0.69.
NASDAQ
Citius Pharmaceuticals' Chief Financial Officer, Jaime Bartushak, reported the grant of 350,000 stock options and existing holdings of various other stock options.
NASDAQ
Citius Pharmaceuticals CEO Leonard Mazur was granted 600,000 stock options and reports holdings of over 10 million common shares and various warrants and options.
NASDAQ
Citius Pharmaceuticals' Chief Medical Officer, Myron Czuczman, was granted 300,000 stock options with an exercise price of $0.38 on November 7, 2024.
NASDAQ
Director Suren G. Dutia of Citius Pharmaceuticals acquired 125,000 stock options on November 7, 2024, as reported in a recent SEC Form 4 filing.
NASDAQ
Director Dennis M. McGrath acquired stock options for 125,000 shares of Citius Pharmaceuticals, Inc. on November 7, 2024.
NASDAQ
Form 4: Citius Pharmaceuticals Vice Chairman Myron Holubiak Reports Stock Option Grants and Holdings
Myron Holubiak, Vice Chairman of Citius Pharmaceuticals, reported the acquisition of new stock options and detailed his existing holdings of common stock and derivative securities.
NASDAQ
Eugene Myron Holuka, a director at Citius Pharmaceuticals, acquired 125,000 stock options at an exercise price of $0.38 on November 7, 2024.
NASDAQ
Form 4: Citius Pharmaceuticals Vice Chairman Myron Z. Holubiak Reports Changes in Beneficial Ownership
Myron Z. Holubiak, Vice Chairman of Citius Pharmaceuticals, reports transactions involving warrants and stock options, including amendments to extend warrant termination dates.
NASDAQ
Form 4: Citius Pharmaceuticals CEO Leonard Mazur Amends Warrant Terms, Maintains Significant Equity Stake
CEO Leonard Mazur amended the terms of existing warrants to extend their expiration dates, while maintaining a substantial ownership position in Citius Pharmaceuticals.
NASDAQ
Eugene Myron Holuka, a director of Citius Pharmaceuticals, exercised stock options and disposed of a small number of shares to cover tax obligations.
NASDAQ
A Citius Pharmaceuticals director, Carol Webb, exercised stock options and disposed of shares to cover tax obligations.
NASDAQ
Citius Oncology files a Form 4 and Power of Attorney with the SEC, detailing changes in beneficial ownership and designating attorneys-in-fact for regulatory filings.
NASDAQ
Form 4: Citius Pharmaceuticals CEO Leonard Mazur Amends Warrant, Acquires Additional Derivative Securities
CEO Leonard Mazur amended a warrant and acquired additional derivative securities in Citius Pharmaceuticals, according to a recent SEC Form 4 filing.
NASDAQ
Form 4: Citius Pharmaceuticals Vice Chairman Myron Z. Holubiak Reports Changes in Beneficial Ownership
Myron Z. Holubiak, Vice Chairman of Citius Pharmaceuticals, files Form 4 detailing warrant amendment and holdings of common stock and stock options.
NASDAQ
Robert Joseph Smith, a director of Citius Pharmaceuticals, acquired 75,000 stock options on March 14, 2024, exercisable at $0.69 per share.